Everence Capital Management Inc. Cuts Stake in Danaher Co. (NYSE:DHR)

Everence Capital Management Inc. lessened its holdings in Danaher Co. (NYSE:DHR) by 26.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,454 shares of the conglomerate’s stock after selling 10,430 shares during the period. Everence Capital Management Inc.’s holdings in Danaher were worth $6,532,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Benjamin Edwards Inc. raised its holdings in Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 38 shares during the last quarter. Wedge Capital Management L L P NC grew its position in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares during the period. Certified Advisory Corp increased its stake in Danaher by 4.5% in the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after purchasing an additional 40 shares during the last quarter. Meridian Financial Partners LLC lifted its position in Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after buying an additional 40 shares during the period. Finally, Kovack Advisors Inc. boosted its stake in Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 1.4 %

DHR stock traded up $3.26 during trading on Friday, reaching $233.07. The stock had a trading volume of 608,634 shares, compared to its average volume of 1,633,422. The firm has a fifty day moving average price of $236.58 and a 200 day moving average price of $254.47. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $168.34 billion, a P/E ratio of 44.48, a PEG ratio of 4.33 and a beta of 0.83. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the firm earned $2.02 EPS. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. Guggenheim began coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Royal Bank of Canada dropped their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. KeyCorp lifted their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Finally, UBS Group lowered their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $287.05.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.